Skip to content
Back to outputs

BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK

Research output: Contribution to journalArticlepeer-review

Standard

BRAF V600 co-testing in thyroid FNA cytology : short-term experience in a large cancer centre in the UK. / Poller, David N.; Glaysher, Sharon; Agrawal, Avi; Caldera, Saliya; Kim, Dae; Yiangou, Constantinos.

In: Journal of Clinical Pathology, Vol. 67, No. 8, 01.08.2014, p. 684-689.

Research output: Contribution to journalArticlepeer-review

Harvard

Poller, DN, Glaysher, S, Agrawal, A, Caldera, S, Kim, D & Yiangou, C 2014, 'BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK', Journal of Clinical Pathology, vol. 67, no. 8, pp. 684-689. https://doi.org/10.1136/jclinpath-2014-202348

APA

Poller, D. N., Glaysher, S., Agrawal, A., Caldera, S., Kim, D., & Yiangou, C. (2014). BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK. Journal of Clinical Pathology, 67(8), 684-689. https://doi.org/10.1136/jclinpath-2014-202348

Vancouver

Poller DN, Glaysher S, Agrawal A, Caldera S, Kim D, Yiangou C. BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK. Journal of Clinical Pathology. 2014 Aug 1;67(8):684-689. https://doi.org/10.1136/jclinpath-2014-202348

Author

Poller, David N. ; Glaysher, Sharon ; Agrawal, Avi ; Caldera, Saliya ; Kim, Dae ; Yiangou, Constantinos. / BRAF V600 co-testing in thyroid FNA cytology : short-term experience in a large cancer centre in the UK. In: Journal of Clinical Pathology. 2014 ; Vol. 67, No. 8. pp. 684-689.

Bibtex

@article{811b6808d808445c8c4f50a8c18f57da,
title = "BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK",
abstract = "Aims: To ascertain whether BRAF V600 mutational analysis is useful for diagnosis of thyroid cancer in thyroid fine needle aspirate (FNA).Methods: Over 8 months thyroid FNAs reported as Thy 3F (neoplasm possible/suggestive of follicular neoplasm), Thy4 (suspicious of malignancy) and Thy 5 (malignant) were tested for BRAF V600 mutation and managed as malignant if mutations were present.Results: Of 207 FNAs from 176 patients, 5 were Thy 5, 19 Thy 4, 36 Thy 3f, 13 Thy 3a, 84 Thy 2 and 50 Thy 1. 11 Thy 3f, 15 Thy 4 and 3 Thy 5 FNAs were tested for BRAF V600 mutation. 0 Thy 3F cases, 6 Thy 4 and 1 Thy 5 (24% of the total tested) showed evidence of mutation. Four patients with BRAF V600 mutation underwent surgery to remove all thyroid tissue, two patients received a lobectomy and one patient is awaiting thyroidectomy. All patients with BRAF V600 mutation were found to have malignancy on final histology, with a diagnostic sensitivity for malignancy excluding coincidental microcarcinoma of 43% and specificity of 100%.Conclusions: BRAF V600 mutational analysis can enable single-stage total thyroidectomy for carcinoma if gene mutation is present in preoperative FNA. BRAF V600 co-testing may reduce the need for completion thyroidectomy with implied cost savings and lower patient morbidity associated with completion thyroidectomy when the cytology is inconclusive but where BRAF V600 mutation is identified in preoperative thyroid FNA.",
keywords = "biopsy, fine-needle, cytodiagnosis, DNA mutational analysis, female, Great Britain, humans, male, proto-oncogene proteins B-raf, thyroid gland, thyroid neoplasms",
author = "Poller, {David N.} and Sharon Glaysher and Avi Agrawal and Saliya Caldera and Dae Kim and Constantinos Yiangou",
note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",
year = "2014",
month = aug,
day = "1",
doi = "10.1136/jclinpath-2014-202348",
language = "English",
volume = "67",
pages = "684--689",
journal = "Journal of Clinical Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "8",

}

RIS

TY - JOUR

T1 - BRAF V600 co-testing in thyroid FNA cytology

T2 - short-term experience in a large cancer centre in the UK

AU - Poller, David N.

AU - Glaysher, Sharon

AU - Agrawal, Avi

AU - Caldera, Saliya

AU - Kim, Dae

AU - Yiangou, Constantinos

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Aims: To ascertain whether BRAF V600 mutational analysis is useful for diagnosis of thyroid cancer in thyroid fine needle aspirate (FNA).Methods: Over 8 months thyroid FNAs reported as Thy 3F (neoplasm possible/suggestive of follicular neoplasm), Thy4 (suspicious of malignancy) and Thy 5 (malignant) were tested for BRAF V600 mutation and managed as malignant if mutations were present.Results: Of 207 FNAs from 176 patients, 5 were Thy 5, 19 Thy 4, 36 Thy 3f, 13 Thy 3a, 84 Thy 2 and 50 Thy 1. 11 Thy 3f, 15 Thy 4 and 3 Thy 5 FNAs were tested for BRAF V600 mutation. 0 Thy 3F cases, 6 Thy 4 and 1 Thy 5 (24% of the total tested) showed evidence of mutation. Four patients with BRAF V600 mutation underwent surgery to remove all thyroid tissue, two patients received a lobectomy and one patient is awaiting thyroidectomy. All patients with BRAF V600 mutation were found to have malignancy on final histology, with a diagnostic sensitivity for malignancy excluding coincidental microcarcinoma of 43% and specificity of 100%.Conclusions: BRAF V600 mutational analysis can enable single-stage total thyroidectomy for carcinoma if gene mutation is present in preoperative FNA. BRAF V600 co-testing may reduce the need for completion thyroidectomy with implied cost savings and lower patient morbidity associated with completion thyroidectomy when the cytology is inconclusive but where BRAF V600 mutation is identified in preoperative thyroid FNA.

AB - Aims: To ascertain whether BRAF V600 mutational analysis is useful for diagnosis of thyroid cancer in thyroid fine needle aspirate (FNA).Methods: Over 8 months thyroid FNAs reported as Thy 3F (neoplasm possible/suggestive of follicular neoplasm), Thy4 (suspicious of malignancy) and Thy 5 (malignant) were tested for BRAF V600 mutation and managed as malignant if mutations were present.Results: Of 207 FNAs from 176 patients, 5 were Thy 5, 19 Thy 4, 36 Thy 3f, 13 Thy 3a, 84 Thy 2 and 50 Thy 1. 11 Thy 3f, 15 Thy 4 and 3 Thy 5 FNAs were tested for BRAF V600 mutation. 0 Thy 3F cases, 6 Thy 4 and 1 Thy 5 (24% of the total tested) showed evidence of mutation. Four patients with BRAF V600 mutation underwent surgery to remove all thyroid tissue, two patients received a lobectomy and one patient is awaiting thyroidectomy. All patients with BRAF V600 mutation were found to have malignancy on final histology, with a diagnostic sensitivity for malignancy excluding coincidental microcarcinoma of 43% and specificity of 100%.Conclusions: BRAF V600 mutational analysis can enable single-stage total thyroidectomy for carcinoma if gene mutation is present in preoperative FNA. BRAF V600 co-testing may reduce the need for completion thyroidectomy with implied cost savings and lower patient morbidity associated with completion thyroidectomy when the cytology is inconclusive but where BRAF V600 mutation is identified in preoperative thyroid FNA.

KW - biopsy, fine-needle

KW - cytodiagnosis

KW - DNA mutational analysis

KW - female

KW - Great Britain

KW - humans

KW - male

KW - proto-oncogene proteins B-raf

KW - thyroid gland

KW - thyroid neoplasms

U2 - 10.1136/jclinpath-2014-202348

DO - 10.1136/jclinpath-2014-202348

M3 - Article

C2 - 24873948

VL - 67

SP - 684

EP - 689

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

IS - 8

ER -

ID: 4757221